Which tumor markers are used in the surveillance for recurrent bladder cancer?

Updated: Sep 10, 2019
  • Author: David A Levy, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print


A host of newer tumor markers and molecular diagnostic indicators has been used, as follows:

  • DNA ploidy and image analysis

  • Chromosomal aneuploidy or polysomy

  • Bladder tumor–associated antigen/analytes

  • Nuclear matrix proteins [7]

  • Monoclonal antibodies (ImmunoCyt)

  • Hyaluronic acid and hyaluronidase

  • Fibrin/fibrinogen degradation product

  • Telomerase [8]

  • Microsatellite instability

  • Phenotypic antigens, including Lewis X, M344, DD23, and T138Ag

  • Growth factors and receptors, including epidermal growth factor receptor, autocrine motility factor, basic fibroblast growth factor

  • Oncogene and tumor suppressor genes

  • Survivin antibody

  • Molecular cytology (fluorescence in situ hybridization [FISH])

A recent review reported the following sensitivities and specificities for commonly available tumor markers [4] :

  • BTAstat - sensitivity 57-83%, specificity 46-73%

  • Nuclear matrix proteins - sensitivity 47-100%, specificity 60-70%

  • ImmunoCyt - sensitivity 86%, specificity 79%

  • Accu-Dx - sensitivity 52-81%, specificity 75-90%

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!